Shares of STAR SPORTS MED (01609) climbed more than 26% at one point during the trading session, before paring gains to trade 16.60% higher at HK$123.60, with turnover reaching HK$180 million. The company announced that it has recently received the CE MDR certification under the European Union Medical Device Regulation, making it the first sports medicine manufacturer in China to secure this certification for its entire product portfolio. Additionally, the company has obtained approvals for multiple product registrations across overseas markets.

The company stated in the announcement that securing these certification and registration documents signifies that a broader range of its products now comply with regulatory requirements in the EU and other target countries. This development is expected to drive further expansion of its overseas business footprint in Europe, Latin America, and Southeast Asia, while strengthening its competitive edge and product positioning in the international marketplace. Earlier, STAR SPORTS MED was officially included in the Stock Connect program and was also selected for inclusion in the Hang Seng Composite Index.

As a leading provider of comprehensive sports medicine solutions in China, STAR SPORTS MED specializes in the research, development, production, and commercialization of sports medicine implants, surgical equipment, and related consumables. According to data from CIC, based on 2024 sales revenue, STAR SPORTS MED ranks as the fourth-largest supplier of sports medicine implants and instruments in China and the largest among domestic manufacturers, holding a market share of 6.5%.